Literature DB >> 29531896

Emerging resistance pathways in lung cancer: what has ROS-1 taught us?

Doraid Alrifai1, Martin D Forster2, Sam M Janes1.   

Abstract

Entities:  

Year:  2018        PMID: 29531896      PMCID: PMC5835638          DOI: 10.21037/tlcr.2017.11.13

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


× No keyword cloud information.
  26 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Authors:  Young Lim Choi; Manabu Soda; Yoshihiro Yamashita; Toshihide Ueno; Junpei Takashima; Takahiro Nakajima; Yasushi Yatabe; Kengo Takeuchi; Toru Hamada; Hidenori Haruta; Yuichi Ishikawa; Hideki Kimura; Tetsuya Mitsudomi; Yoshiro Tanio; Hiroyuki Mano
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.

Authors:  Vivek Subbiah; David S Hong; Funda Meric-Bernstam
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-25       Impact factor: 11.205

4.  Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.

Authors:  Maria Debiec-Rychter; Jan Cools; Herlinde Dumez; Raf Sciot; Michel Stul; Nicole Mentens; Hilde Vranckx; Bartosz Wasag; Hans Prenen; Johannes Roesel; Anne Hagemeijer; Allan Van Oosterom; Peter Marynen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

5.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

6.  Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Authors:  Sai-Hong Ignatius Ou; Jin Seok Ahn; Luigi De Petris; Ramaswamy Govindan; James Chih-Hsin Yang; Brett Hughes; Hervé Lena; Denis Moro-Sibilot; Alessandra Bearz; Santiago Viteri Ramirez; Tarek Mekhail; Alexander Spira; Walter Bordogna; Bogdana Balas; Peter N Morcos; Annabelle Monnet; Ali Zeaiter; Dong-Wan Kim
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

7.  Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Authors:  Mark M Awad; Ryohei Katayama; Michele McTigue; Wei Liu; Ya-Li Deng; Alexei Brooun; Luc Friboulet; Donghui Huang; Matthew D Falk; Sergei Timofeevski; Keith D Wilner; Elizabeth L Lockerman; Tahsin M Khan; Sidra Mahmood; Justin F Gainor; Subba R Digumarthy; James R Stone; Mari Mino-Kenudson; James G Christensen; A John Iafrate; Jeffrey A Engelman; Alice T Shaw
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

8.  Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

Authors:  Suresh S Ramalingam; James C-H Yang; Chee Khoon Lee; Takayasu Kurata; Dong-Wan Kim; Thomas John; Naoyuki Nogami; Yuichiro Ohe; Helen Mann; Yuri Rukazenkov; Serban Ghiorghiu; Daniel Stetson; Aleksandra Markovets; J Carl Barrett; Kenneth S Thress; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2017-08-25       Impact factor: 44.544

9.  EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice.

Authors:  S Gahr; R Stoehr; E Geissinger; J H Ficker; W M Brueckl; A Gschwendtner; S Gattenloehner; F S Fuchs; C Schulz; R J Rieker; A Hartmann; P Ruemmele; W Dietmaier
Journal:  Br J Cancer       Date:  2013-09-03       Impact factor: 7.640

10.  A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.

Authors:  Alexander Drilon; Romel Somwar; Jacob P Wagner; Nadeem A Vellore; Christopher A Eide; Matthew S Zabriskie; Maria E Arcila; Jaclyn F Hechtman; Lu Wang; Roger S Smith; Mark G Kris; Gregory J Riely; Brian J Druker; Thomas O'Hare; Marc Ladanyi; Monika A Davare
Journal:  Clin Cancer Res       Date:  2015-12-16       Impact factor: 12.531

View more
  1 in total

1.  Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Authors:  D G Bebb; J Agulnik; R Albadine; S Banerji; G Bigras; C Butts; C Couture; J C Cutz; P Desmeules; D N Ionescu; N B Leighl; B Melosky; W Morzycki; F Rashid-Kolvear; Clin Lab; H S Sekhon; A C Smith; T L Stockley; E Torlakovic; Z Xu; M S Tsao
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.